MTVA

MetaVia Inc

May 19 • 12:27PM ET

1.71

+0.60 54.05 %

Healthcare • Biotechnology • USA • Nano • NASD

Today, 4:05 AMLate-breaking ADA 2026 abstract acceptances for DA-1726 spark MetaVia's premarket surge.

Peers: TNXP AEMD BCDA SABS SNOA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.02	Insider Own	35.28%	Shs Outstand	5.16M	Perf Week	76.29%
Market Cap	8.83M	Forward P/E	-	EPS next Y	-2.41	Insider Trans	0.00%	Shs Float	3.34M	Perf Month	13.25%
Enterprise Value	-4.71M	PEG	-	EPS next Q	-0.82	Inst Own	1.30%	Short Float	2.42%	Perf Quarter	11.04%
Income	-13.12M	P/S	-	EPS this Y	66.35%	Inst Trans	0.03%	Short Ratio	0.56	Perf Half Y	-77.77%
Sales	0.00M	P/B	0.97	EPS next Y	2.70%	ROA	-99.00%	Short Interest	0.08M	Perf YTD	-79.69%
Book/sh	1.76	P/C	0.64	EPS next 5Y	40.10%	ROE	-195.12%	52W High	19.03 -91.01%	Perf Year	-77.76%
Cash/sh	2.66	P/FCF	-	EPS past 3/5Y	75.13% 72.69%	ROIC	-142.73%	52W Low	0.97 77.00%	Perf 3Y	-96.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.69% 9.60%	Perf 5Y	-99.98%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	83.72%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.73	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.05	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.73	EPS Q/Q	80.00%	SMA20	25.23%	Beta	0.56	Target Price	19.33
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	23.52%	Rel Volume	1011.65	Prev Close	1.11
Employees	8	LT Debt/Eq	0.01	Earnings	May 14 AMC	SMA200	-70.86%	Avg Volume	143.79K	Price	1.71
IPO	Aug 05, 2016	Option/Short	No / No	EPS/Sales Surpr.	-6.28% -	Trades		Volume	69,990,850	Change	54.05%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Resumed	H.C. Wainwright	Buy	$12
Dec-30-24	Initiated	H.C. Wainwright	Buy	$12

May-18-26 08:31AM	MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions (PR Newswire)
May-14-26 04:05PM	MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire) -6.72%
May-11-26 08:31AM	MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 (PR Newswire)
Apr-10-26 08:30AM	MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity (PR Newswire) +18.49%
Mar-26-26 08:31AM	MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update (PR Newswire)
08:00AM	Loading…
Mar-18-26 08:00AM	MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control (PR Newswire)
Mar-12-26 09:01AM	MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 (PR Newswire)
Mar-04-26 08:31AM	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum (PR Newswire)
Feb-17-26 09:01AM	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference (PR Newswire) -6.10%
Feb-13-26 12:39PM	MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug (Benzinga)
08:31AM	MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 (PR Newswire)
Feb-04-26 08:00AM	MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel (PR Newswire)
Jan-16-26 04:01PM	MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option (PR Newswire) -5.76%
Jan-15-26 09:32AM	MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering (PR Newswire) -39.11%
Jan-05-26 08:30AM	MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile (PR Newswire) -8.68%
08:31AM	Loading…
Dec-29-25 08:31AM	MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference (PR Newswire)
Dec-22-25 08:31AM	MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +11.60%
Dec-02-25 08:45AM	MetaVia Inc. Announces 1-for-11 Reverse Stock Split (PR Newswire) -20.07%
Nov-07-25 08:31AM	MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting 2025 (PR Newswire) +6.85%
Nov-06-25 08:31AM	MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) -15.00%
Nov-04-25 04:01PM	MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek 2025 (PR Newswire) +8.00% -7.41%
Oct-27-25 08:31AM	MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting (PR Newswire)
Oct-20-25 08:31AM	MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek 2025 (PR Newswire)
Oct-14-25 08:31AM	MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference (PR Newswire)
Aug-26-25 08:31AM	MetaVia to Present at Upcoming Investor and Industry Conferences (PR Newswire)
Aug-07-25 08:31AM	MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-06-25 08:31AM	MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient (PR Newswire)
Aug-04-25 08:31AM	MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 (PR Newswire)
Jul-09-25 08:31AM	MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose (PR Newswire) +8.21%
Jun-21-25 09:00AM	MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session (PR Newswire)
08:35AM	Loading…
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire)
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire) +7.73%
08:31AM	MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th (GlobeNewswire)
Jun-04-25 08:31AM	MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions (PR Newswire)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-14-25 04:05PM	MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-09-25 08:01AM	MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (PR Newswire)
May-07-25 02:00AM	MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 (PR Newswire) -8.05%
Apr-23-25 08:31AM	MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 (PR Newswire) +8.40%
Apr-22-25 08:31AM	MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential (PR Newswire)
Apr-15-25 07:01AM	MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability (PR Newswire) -55.98%
Mar-20-25 07:31AM	MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jan-10-25 08:05AM	MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference (PR Newswire)
Dec-19-24 08:01AM	MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire)
Dec-18-24 08:01AM	MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire) -17.73%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 08:01AM	MetaVia to Present at the Emerging Growth Conference in December (PR Newswire)

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

CEOMr. Hyung Heon Kim

Chief Financial OfficerMr. Marshall H. Woodworth

Chief Scientific OfficerDr. Mi-Kyung Kim

Senior Vice President of Clinical OperationsMr. Robert Homolka

Consulting Chief Medical Officer & AdvisorDr. W. Christopher Fang M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Woodworth Marshall H	Chief Financial Officer	Jun 04 '25	Buy	0.70	14,200	9,940	44,279	Jun 04 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTVA

MetaVia Inc

Upgrade your Finviz experience